<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04192435</url>
  </required_header>
  <id_info>
    <org_study_id>087</org_study_id>
    <nct_id>NCT04192435</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery</brief_title>
  <acronym>TRIGS</acronym>
  <official_title>Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery; The TRIGS Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This international, multicentre, pragmatic, double-blind, placebo-controlled, randomised
      trial of TxA versus placebo will enrol 3,300 patients throughout Australia and
      internationally. This is an effectiveness trial - some elements of the trial are deliberately
      left to the perioperative clinicians' discretion in order to reflect usual practice and
      maximise generalisability.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Aims: To conduct a large, multicentre clinical trial of tranexamic acid (TxA), an
      antifibrinolytic drug routinely used to reduce bleeding in cardiac and some orthopaedic
      surgery, in 3,300 patients undergoing major gastrointestinal (GI) surgery. Our specific aims
      are to investigate whether TxA:

      Aim 1: Reduces surgical site infection (&quot;wound infection&quot;), and other healthcare-associated
      infections (pneumonia and sepsis).

      Aim 2: Reduces red cell transfusion in GI surgery. Aim 3: Reduces a pooled composite of any
      serious postoperative complications, and so increases &quot;days alive and at home up to 30 days
      after surgery&quot; (DAH30).

      Aim 4: To evaluate the temporal effect of TxA on perioperative immune and inflammatory
      responses.

      Study Hypothesis Prophylactic TxA administration in patients undergoing major GI surgery
      reduces the incidence of surgical site infection (SSI) after surgery when compared with
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blind, placebo-controlled, randomised trial of TxA versus placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Matched TxA and placebo vials</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Surgical Site Infection</measure>
    <time_frame>from surgical incision to 30 days post surgical incision</time_frame>
    <description>defined by the US Centers for Disease Control (CDC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red cell transfusion</measure>
    <time_frame>from surgical incision to hospital discharge (from index surgery) or 30 days.</time_frame>
    <description>Total units given</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other healthcare-associated infections</measure>
    <time_frame>from surgical incision to 30 days</time_frame>
    <description>sepsis, pneumonia, blood stream infection, UTI, etc; all using CDC-guided definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>Postoperative Day 3 (three days after surgical incision)</time_frame>
    <description>peak</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days at home up to 30 days after surgery (DAH30).</measure>
    <time_frame>From surgical incision to 30 days</time_frame>
    <description>Time that patient spends at home in the 30 days following surgery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">3300</enrollment>
  <condition>Infection Wound</condition>
  <condition>Gastrointestinal Complication</condition>
  <condition>Anesthesia</condition>
  <condition>Bleeding</condition>
  <condition>Healthcare Associated Infection</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>At induction of anesthesia and prior to surgical incision a bolus of 0.15 ml/kg ( up to a maximum of 15 ml) , and then commence an infusion of 0.05 ml/kg/h until the end of surgery. The total maximal administered study drug volume will be 30 ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>100mg/ml</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Placebo will be 5ml vials calculated to equivalent to the 100mg/ml of active drug.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Adult patients scheduled for elective or semi-elective (inpatient) open or lap-assisted
        GI surgery (oesophageal, gastric, hepatobiliary, colorectal) with one or more risk factors
        for complications:

          -  Age ≥70 years

          -  ASA physical status 3 or 4

          -  Known or suspected history of: heart failure, diabetes, peripheral vascular disease,
             or chronic respiratory disease

          -  Obesity (BMI ≥30 kg/m2)

          -  Anaemia (preoperative haemoglobin &lt;130 g/l in males and &lt;120 g/l in females)

          -  Renal impairment (se. creatinine ≥150mol/l)

          -  Low albumin (&lt;30 g/L)

        Exclusion Criteria:

          -  Poor spoken and or written language comprehension

          -  Laparoscopic cholecystectomy and other minor (eg. closure of stoma) surgery

          -  Pre-existing infection/sepsis

          -  Known history of: spontaneous pulmonary embolism, arterial thrombosis familial
             thrombophilia (e.g. Lupus anticoagulant, protein C deficiency, factor V Leiden)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul S Myles, MD, DSc</last_name>
    <role>Study Chair</role>
    <affiliation>Alfred Hospital and Monash University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul S Myles, MD, DSc</last_name>
    <phone>+61390763176</phone>
    <phone_ext>3176</phone_ext>
    <email>p.myles@alfred.org.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie KA Wallace, MPH, RN</last_name>
    <phone>+61390763176</phone>
    <phone_ext>62651</phone_ext>
    <email>s.wallace@alfred.org.au</email>
  </overall_contact_backup>
  <reference>
    <citation>Draxler DF, Yep K, Hanafi G, Winton A, Daglas M, Ho H, Sashindranath M, Wutzlhofer LM, Forbes A, Goncalves I, Tran HA, Wallace S, Plebanski M, Myles PS, Medcalf RL. Tranexamic acid modulates the immune response and reduces postsurgical infection rates. Blood Adv. 2019 May 28;3(10):1598-1609. doi: 10.1182/bloodadvances.2019000092.</citation>
    <PMID>31126915</PMID>
  </reference>
  <reference>
    <citation>Bell M, Eriksson LI, Svensson T, Hallqvist L, Granath F, Reilly J, Myles PS. Days at Home after Surgery: An Integrated and Efficient Outcome Measure for Clinical Trials and Quality Assurance. EClinicalMedicine. 2019 Apr 27;11:18-26. doi: 10.1016/j.eclinm.2019.04.011. eCollection 2019 May-Jun.</citation>
    <PMID>31317130</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>December 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>April 19, 2020</last_update_submitted>
  <last_update_submitted_qc>April 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Cross Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>This decision will be made on a individual case by case basis, with formal request and review by the PI and steering committee.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Before recruitment of final patient</ipd_time_frame>
    <ipd_access_criteria>Patient and illness eligibility</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

